As cancer progresses, the 10-year relative survival rate decreases. The lymphatic drug delivery system we developed is useful for treating metastatic lymph nodes at the early stage (regional).

The Pharmaceuticals and Medical Devices Agency (PMDA) approved a phase 1 clinical trial for the treatment of head and neck cancer in 2018. We are currently recruiting pharmaceutical companies that wish to participate in the trial.